Special Issue "Latest Advances in Pancreatic Diseases"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Gastroenterology & Hepatology".

Deadline for manuscript submissions: 1 August 2021.

Special Issue Editor

Dr. Octavio Caba
E-Mail Website
Guest Editor
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain
Interests: pancreatic ductal adenocarcinoma; chronic pancreatitis; peripheral blood; biomarkers; diagnosis; RNASeq; metabolomics

Special Issue Information

Dear Colleagues,

Despite decades of effort, the diagnosis and management of the diseases of the pancreas is still a challenge due to the inaccessibility of this organ. There are multiple methods to evaluate the pancreas, but to date, few of them confirm the presence of any pancreatic disease or can help in monitoring treatment success.  

Pancreatic cancer remains a lethal disease due to its rapid progression and early metastasis, with a life expectancy of less than 6 months and a 5-year survival rate of around 5%. Pancreatitis is an inflammatory disease of the pancreas. Its diagnosis, mainly based on the presence of morphological or functional changes, is difficult because no standard diagnostic criteria or method of diagnosing this pathology have been established. Diabetes is a disease characterized by β-cell destruction or dysfunction, resulting in progressive hyperglycemia. Finally, exocrine pancreatic insufficiency results from destruction of the pancreatic parenchyma, making it impossible to maintain the minimum production levels of digestive enzymes.

As early diagnosis is the best way to improve the clinical outcome of these patients, the lack of robust, accurate, and non-invasive methods to detect early stages of pancreatic diseases represents the most important obstacle to the improvement of outcomes. The present Issue aims to publish studies that propose new diagnostic or prognostic tools in the battle against pancreatic diseases.

Dr. Octavio Caba
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic diseases
  • pancreatic cancer
  • pancreatitis
  • diabetes
  • exocrine pancreatic insufficiency
  • biomarkers
  • diagnosis
  • prognosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
State of the Art in Exocrine Pancreatic Insufficiency
Medicina 2020, 56(10), 523; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina56100523 - 07 Oct 2020
Cited by 1 | Viewed by 772
Abstract
Exocrine pancreatic insufficiency (EPI) is defined as the maldigestion of foods due to inadequate pancreatic secretion, which can be caused by alterations in its stimulation, production, transport, or interaction with nutrients at duodenal level. The most frequent causes are chronic pancreatitis in adults [...] Read more.
Exocrine pancreatic insufficiency (EPI) is defined as the maldigestion of foods due to inadequate pancreatic secretion, which can be caused by alterations in its stimulation, production, transport, or interaction with nutrients at duodenal level. The most frequent causes are chronic pancreatitis in adults and cystic fibrosis in children. The prevalence of EPI is high, varying according to its etiology, but it is considered to be underdiagnosed and undertreated. Its importance lies in the quality of life impairment that results from the malabsorption and malnutrition and in the increased morbidity and mortality, being associated with osteoporosis and cardiovascular events. The diagnosis is based on a set of symptoms, indicators of malnutrition, and an indirect non-invasive test in at-risk patients. The treatment of choice combines non-restrictive dietary measures with pancreatic enzyme replacement therapy to correct the associated symptoms and improve the nutritional status of patients. Non-responders require the adjustment of pancreatic enzyme therapy, the association of proton pump inhibitors, and/or the evaluation of alternative diagnoses such as bacterial overgrowth. This review offers an in-depth overview of EPI in order to support the proper management of this entity based on updated and integrated knowledge of its etiopathogenesis, prevalence, diagnosis, and treatment. Full article
(This article belongs to the Special Issue Latest Advances in Pancreatic Diseases)
Show Figures

Figure 1

Back to TopTop